Fletcher Aaron G.L.'s Form 4 filing
TFF Pharmaceuticals, Inc. (TFFP) · filed Apr 4, 2022
- Accession no.
- 0001213900-22-017959
- Filed
- Apr 4, 2022
- Trade date
- Apr 4, 2022
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market purchases total $3.50M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Fletcher Aaron G.L.CIK 0001789490 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 4, 2022 | Common Stock | PPurchaseAcquired | +500,000 | $6.43 | +$3,215,000 | 500,000 | Indirect | |
| Apr 4, 2022 | Common Stock | PPurchaseAcquired | +42,000 | $6.89F2 | +$289,380 | 542,000 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The reported shares were purchased, and are owned, directly by Bios Special Opportunity Fund, LP. The reported shares were purchased in the open market in multiple transactions at prices ranging from $6.52 to $7.15. The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to TFF Pharmaceuticals, Inc., any stockholder of TFF Pharmaceuticals, Inc or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2). Dr. Fletcher disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Dr. Fletcher is the beneficial owner of any securities covered by this Form 4.
Referenced by the price of 1 transaction in Table I.